Unity Biotechnology, Inc. (UBX) financial statements (2021 and earlier)

Company profile

Business Address 3280 BAYSHORE BOULEVARD
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments127113128150171178186
Cash and cash equivalents37372334152934
Short-term investments9076105116156149152
Other undisclosed current assets213132222
Total current assets:129126141152173180188
Noncurrent Assets
Property, plant and equipment17566667
Long-term investments and receivables374  612
Long-term investments374  612
Restricted cash and investments1111111
Other noncurrent assets1222222
Total noncurrent assets:221613981521
TOTAL ASSETS:151142154161181195208
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:51313115109
Accounts payable5554532
Accrued liabilities5555555
Employee-related liabilities6432432
Settlement liabilities    2  
Other undisclosed accounts payable and accrued liabilities(11)   (11)  
Other undisclosed current liabilities121201221
Total current liabilities:1714151117129
Noncurrent Liabilities
Liabilities, other than long-term debt1313122333
Deferred rent credit1313122233
Other liabilities  00000
Other undisclosed noncurrent liabilities   1211
Total noncurrent liabilities:1313123444
Total liabilities:31272714211513
Stockholders' equity
Stockholders' equity attributable to parent, including:121115127147161180195
Common stock0000000
Additional paid in capital367343333329325322319
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(245)(227)(206)(182)(163)(141)(123)
Other undisclosed stockholders' equity attributable to parent(1)(1)(1)(1)(1)(1)(1)
Total stockholders' equity:121115127147161180195
TOTAL LIABILITIES AND EQUITY:151142154161181195208

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(23)(22)(24)(20)(23)(19)(21)
Operating loss:(23)(22)(24)(20)(23)(19)(21)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
4(0)(0)(0)(0)(0)(0)
Net loss:(19)(22)(25)(20)(23)(19)(21)
Other undisclosed net income attributable to parent1111111
Net loss available to common stockholders, diluted:(18)(22)(24)(19)(22)(18)(20)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(19)(22)(25)(20)(23)(19)(21)
Comprehensive loss:(19)(22)(25)(20)(23)(19)(21)
Other undisclosed comprehensive income, net of tax, attributable to parent1111111
Comprehensive loss, net of tax, attributable to parent:(18)(22)(24)(19)(22)(18)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: